Geron Q1 Earnings Call Highlights

1 hour ago 2

MarketBeat

Wed, May 6, 2026 astatine 8:07 AM CDT 8 min read

Geron logo

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) reported first-quarter 2026 nett gross of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, arsenic the institution continued to standard commercialization of Rytelo successful the U.S. Management reiterated full-year 2026 guidance and outlined ongoing enactment to measure a European commercialization approach, portion besides previewing expected milestones for its Phase 3 myelofibrosis program.

Rytelo gross maturation and 2026 guidance reiterated

Chief Executive Officer Harout Semerjian said Geron made advancement connected its 2026 strategical priorities successful the 4th by increasing Rytelo done “focused commercialized execution” and advancing its European strategy “while maintaining our fiscal discipline.”

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Chief Financial Officer Michelle Robertson said full nett gross for the 3 months ended March 31, 2026 was $61.8 million, compared with $39.6 cardinal successful the prior-year period. Geron reiterated its 2026 nett gross guidance for Rytelo of $220 cardinal to $240 million, with Robertson noting that “a greater information of growth” is anticipated successful the backmost fractional of the year.

Robertson besides highlighted a displacement successful gross-to-net dynamics arsenic measurement increased. Gross-to-net reductions roseate to 21% successful the 4th from 13% a twelvemonth earlier, driven by “wider 340B utilization and expanded GPO contracting.” For the remainder of 2026, she said the institution expects gross-to-net to beryllium successful the “low to mid 20s.”

U.S. commercialized execution focuses connected second-line lower-risk MDS

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

Chief Commercial Officer Ahmed ElNawawi said first-quarter request grew 6% quarter-over-quarter and that prescribing accounts accrued astir 12%, expanding the company’s footprint since motorboat to astir 1,450 accounts.

ElNawawi said Geron estimates the second-line lower-risk MDS accidental astatine astir 8,000 patients successful the U.S., calling that conception the company’s “primary commercialized focus” and noting the strategy is supported by existent NCCN guidelines. He added that the institution is seeking to scope patients “at the close constituent successful their attraction travel erstwhile they are astir apt to benefit.”

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

He described 3 halfway commercialized initiatives:

Targeted engagement with high-volume assemblage accounts, prioritizing centers treating earlier-line and second-line patients portion besides utilizing integer tactics for lower-volume accounts.
Increased concern successful selling channels, with an accent connected digital, non-personal promotion, and third-party acquisition platforms to make a “3-D situation sound” approach.
Cross-functional relationship management that uses information presented astatine ASH 2025 to code cytopenias and presumption Rytelo arsenic modular of attraction successful due second-line patients, “regardless of their RS.”